In a phase 3 trial of 587 patients with relapsed or refractory multiple myeloma after 1-3 lines, teclistamab-daratumumab improved PFS versus DPd or DVd (estimated 36-month PFS 83.4% vs 29.7%; HR 0.17). Serious adverse events: 70.7% vs 62.4%.
RCTn = 587 patients
Costa et al. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma